Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic

被引:12
|
作者
Upadhyay S.K. [1 ]
Dan S. [2 ]
Girdhar M. [1 ]
Rastogi K. [3 ]
机构
[1] Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, 133207, HR
[2] Department of Biotechnology, I.K. Gujral Punjab Technical University, Jalandhar, Punjab
[3] Department of Pharmacology, KIET Group of Institutions, Ghaziabad, 201206, Delhi-NCR
关键词
COVID-19; Nano-based diagnosis; Nanomedicine; Nanovaccines; SARS-CoV-2;
D O I
10.1007/s40495-021-00250-z
中图分类号
学科分类号
摘要
Purpose of Review: The coronavirus disease-2019 (COVID-19) is a global pandemic which has not been seen in recent history, leaving behind deep socioeconomic damages and huge human losses with the disturbance in the healthcare sector. Despite the tremendous international effort and the launch of various clinical trials for the containment of this pandemic, no effective therapy has been proven yet. Recent Findings: This review has highlighted the different traditional therapeutic techniques, along with the potential contribution of nanomedicine against the severe acute respiratory syndrome corovirus-2 (SARS-CoV-2). Repositioning of the drugs, such as remdesivir and chloroquine, is a rapid process for the reach of safe therapeutics, and the related clinical trials have determined effects against COVID-19. Various protein-based SARS-CoV-2 vaccine candidates have successfully entered clinical phases, determining positive results. The self-assembled and metallic nanovaccines mostly based on the antigenic properties of spike (S) protein are also approachable, feasible, and promising techniques for lowering the viral burden. Summary: There are number of NP-based diagnostic systems have been reported for coronaviruses (CoVs) and specifically for SARS-CoV-2. However, extensive studies are still necessary and required for the nanoparticle (NP)-based therapy. © 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 50 条
  • [1] SARS-CoV-2 and the pandemic of COVID-19
    Adil, Md Tanveer
    Rahman, Rumana
    Whitelaw, Douglas
    Jain, Vigyan
    Al-Taan, Omer
    Rashid, Farhan
    Munasinghe, Aruna
    Jambulingam, Periyathambi
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2021, 97 (1144) : 110 - 116
  • [2] SARS-CoV-2/COVID-19 pandemic produces a new paradigm for international hematopathology meetings
    Macon, William R.
    [J]. JOURNAL OF HEMATOPATHOLOGY, 2021, 14 (02) : 95 - 95
  • [3] SARS-CoV-2/COVID-19 pandemic produces a new paradigm for international hematopathology meetings
    William R. Macon
    [J]. Journal of Hematopathology, 2021, 14 : 95 - 95
  • [4] COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic
    Bhavana, Valamla
    Thakor, Pradip
    Singh, Shashi Bala
    Mehra, Neelesh Kumar
    [J]. LIFE SCIENCES, 2020, 261
  • [5] Persistence of SARS-CoV-2: a new paradigm of COVID-19 management
    Alhusseini, L. B.
    Yassen, L. T.
    Kouhsari, E.
    Al Marjani, M. F.
    [J]. ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITA, 2021, 33 (05): : 426 - 432
  • [6] Overview of SARS-CoV-2 and COVID-19 Vaccine
    Alhaibil, Nada Abdullah
    [J]. BAHRAIN MEDICAL BULLETIN, 2021, 43 (02) : 511 - 515
  • [7] The evolution of SARS-CoV-2 and the COVID-19 pandemic
    Si, Yuanfang
    Wu, Weidong
    Xue, Xia
    Sun, Xiangdong
    Qin, Yaping
    Li, Ya
    Qiu, Chunjing
    Li, Yingying
    Zhuo, Ziran
    Mi, Yang
    Zheng, Pengyuan
    [J]. PEERJ, 2023, 11
  • [8] The evolution of SARS-CoV-2 and the COVID-19 pandemic
    Si, Yuanfang
    Wu, Weidong
    Xue, Xia
    Sun, Xiangdong
    Qin, Yaping
    Li, Ya
    Qiu, Chunjing
    Li, Yingying
    Zhuo, Ziran
    Mi, Yang
    Zheng, Pengyuan
    [J]. PEERJ, 2023, 11
  • [9] In Focus: SARS-CoV-2 and the COVID-19 Pandemic
    Giunta, Riccardo E.
    [J]. HANDCHIRURGIE MIKROCHIRURGIE PLASTISCHE CHIRURGIE, 2020, 52 (03) : 220 - 220
  • [10] SARS-CoV-2: Remarks on the COVID-19 Pandemic
    Egbert Piasecki
    [J]. Archivum Immunologiae et Therapiae Experimentalis, 2020, 68